Close Menu

CHICAGO (GenomeWeb) – Genomic analytics startup Farsight Genome Systems has high ambitions, seeking to gain US Food and Drug Administration clearance of its software for use in labs conducting sequencing-based tests.

"We would like to be the first analytic pipeline that has won FDA clearance," CEO and Founder Glenda Anderson said.

Sunnyvale, California-based Farsight, founded in 2015, has submitted a first demonstration of its Farsight Correo platform to the FDA, according to Anderson, as it seeks 510(k) clearance for the technology.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.